{
    "organizations": [],
    "uuid": "4ce66645e1518816a9ae5a02cfe0235050424c5b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eyegate-announces-top-line-results/brief-eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery-idUSASB0C3Y4",
    "ord_in_thread": 0,
    "title": "BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 5, 2018 / 1:49 PM / in 19 minutes BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery Reuters Staff \nFeb 5 (Reuters) - Eyegate Pharmaceuticals Inc: \n* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY \n* EYEGATE PHARMACEUTICALS INC - IN THE PHASE 2B STUDY, EGP-437 DEMONSTRATED A HIGHER RATE OF SUCCESS COMPARED TO VEHICLE AT ALL TIME POINTS \n* EYEGATE- CO-PRIMARY ENDPOINTS OF SUBJECT PROPORTIONS WITH DAY 7 ACC COUNT 0, SUBJECTS WITH PAIN SCORE 0 AT DAY 1 DIDN‘T SHOW STATISTICAL SIGNIFICANCE​ \n* EYEGATE - ‍EGP-437 SHOWED NUMERICALLY BETTER CLINICAL EFFICACY, DEFINED AS ACC COUNT OF ZERO, THROUGHOUT STUDY, ESPECIALLY AT DAY 14, BEYOND​ \n* EYEGATE - ‍FOR SECONDARY ENDPOINTS, EGP-437 SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN ACC COUNT AND PAIN SCORE, ON DAY 7 AND DAY 1 RESPECTIVELY​ \n* EYEGATE PHARMACEUTICALS INC - ‍EGP-437 ARM DEMONSTRATED A FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS REPORTED​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-05T15:49:00.000+02:00",
    "crawled": "2018-02-05T16:12:57.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "announces",
        "result",
        "phase",
        "2b",
        "trial",
        "cataract",
        "surgery",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "eyegate",
        "pharmaceutical",
        "inc",
        "eyegate",
        "announces",
        "result",
        "phase",
        "2b",
        "trial",
        "cataract",
        "surgery",
        "eyegate",
        "pharmaceutical",
        "inc",
        "phase",
        "2b",
        "study",
        "demonstrated",
        "higher",
        "rate",
        "success",
        "compared",
        "vehicle",
        "time",
        "point",
        "endpoint",
        "subject",
        "proportion",
        "day",
        "acc",
        "count",
        "subject",
        "pain",
        "score",
        "day",
        "show",
        "statistical",
        "eyegate",
        "showed",
        "numerically",
        "better",
        "clinical",
        "efficacy",
        "defined",
        "acc",
        "count",
        "zero",
        "throughout",
        "study",
        "especially",
        "day",
        "eyegate",
        "secondary",
        "endpoint",
        "showed",
        "statistically",
        "significant",
        "improvement",
        "acc",
        "count",
        "pain",
        "score",
        "day",
        "day",
        "eyegate",
        "pharmaceutical",
        "inc",
        "arm",
        "demonstrated",
        "favorable",
        "safety",
        "profile",
        "serious",
        "adverse",
        "event",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}